The Global Anxiety Disorders Market 2015-2019 research report, now available with ReportsnReports.com, says that in addition to emerging markets' focus, the key vendors are trying to penetrate the market by organizing awareness drives and by offering reimbursements codes for their products.
Analysts forecast the Global Anxiety Disorders market to grow at a CAGR of 4.02% over the period 2014-2019. According to the report, increased patient population is one of the main drivers of Anxiety disorders market which is expected to drive the sales of anti-anxiety drugs thereby driving the market. Decreased stability in relationships, increased mechanization, disrupted work-life balance, sleep deprivation and decreased outdoor activities are predisposing people to anxiety disorders.
ICD is a standard tool used for diagnostic and analytical purposes. These codes can be used to emphasize the need for patient visits to medical centers. They can also be used by insurance companies to understand the frequency of medical visits recommended for patients. ICD-10 codes have been designed to provide enhanced specificity and better clinical details than ICD-9 codes. These codes ensure better interpretation of physicians' documentation by auditors, third parties, and attorneys. ICD-10-CM codes are also anticipated to provide comprehensive healthcare data, thus promoting the development of advanced disease protocols and clinical pathways.
Recently, the market has witnessed increase in investments in these countries with the intention of enhancing the market hold in these territories. Anxiety is associated with uneasiness, fearfulness, and tension. Mild anxiety, for example, associated with exams or interview, is normal and triggers 'fight or flight' response. Anxiety without an identifiable cause, anxiety which persists even after the stressful condition is over, and anxiety which is out of proportion of the stressful condition indicates abnormal anxiety. However, severe and persistent anxiety can interfere with everyday activities and might lead to other psychic problems. Anxiety disorder market is a mental health disorder characterized by the presence of anxiety. These disorders might occur simultaneously with other disorders such as depression, or along with drug abuse. Order a copy of this report at (Prices start at US $ 2500 for a single user PDF) http://www.reportsnreports.com/Purchase.aspx?name=327267 .
This report covers the present scenario and the growth prospects of the Global Anxiety Disorders market for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of drugs approved for the treatment of the following anxiety disorders:
- GAD
- Panic Disorder
- OCD
- PTSD
- Social Anxiety Disorder
- Special Phobias
- BDD
The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Anxiety Disorders market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
Global Anxiety Disorders Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Anxiety Disorders market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Further, the report states that one of the major challenges that the market faces is the low rate of diagnosis. Anxiety disorders are associated with low rate of diagnosis because they are usually asymptomatic during the initial phases of progression. Lack of diagnosis delays the initiation of treatment and also deteriorates the quality of life of patients.
Key players in the Global Anxiety Disorders Market are Eli Lilly and Co., GlaxoSmithKline plc and Pfizer Inc.
Other Prominent Vendors in the market are Abbott Laboratories, Actavis, Baxter International, F. Hoffmann-La Roche, Noven Pharmaceuticals, Recordati Rare Diseases, Shionogi and Sumitomo Dainippon Pharma.
